Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

HIV Infections Clinical Trial

Official title:

Randomised, Double-blind, Placebo-controlled 7 Day Monotherapy Phase IIa Study to Evaluate the Antiviral Activity and Safety of Increasing Doses of Oral Administered RTV-boosted BILR 355 BS (75 mg and 150 mg Twice Daily) in HIV-1-infected, NNRTI-experienced Patients, Followed by 28 Day Combination Therapy With Tipranavir or Lopinavir Based HAART-regimen

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00294372
• Other study ID #: 1188.31
• Status: Terminated
• Phase: Phase 2
• First received: February 20, 2006
• Last updated: November 13, 2013
• Start date: February 2006

Study information

• Verified date: November 2013
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 36
• Est. primary completion date: September 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation.

2. HIV-1 infected males or females >= 18 years of age.

3. History of NNRTI based HAART >= 8 weeks and at least one, but not more than 3 NNRTI-associated resistance mutations by current genotype

4. TPV/r or LPV/r susceptible

5. CD4+ T lymphocyte count >= 100 cells/?l.

7. HIV-1 viral load >= 2000 copies/mL at screening. 8. Karnofsky score >= 70 9. Based on the antiviral resistance profile of the patients virus, the investigator must be able to construct a background HAART treatment regimen (OBR) such that the patient will receive 3 effective ARV drugs, in addition to his study medication.

10. Acceptable screening laboratory values (Visit 1) that indicate adequate baseline organ function. Laboratory values are considered to be acceptable if the following apply: Absolute neutrophil count (ANC) >750/mm3 Hemoglobin >= 10 g/dL Platelet count >99,000/mm3 AST, ALT , and alkaline phosphatase < 2.5xULN >= DAIDS Grade 1) Total bilirubin <2.5xULN Serum amylase <1.5xULN 11. Acceptable medical history, as assessed by the investigator, with chest x-ray results and ECG within 1 year of study participation.

12. Willingness to abstain from ingesting substances which may alter plasma study drug levels by interaction with the cytochrome P450 system 13. A prior AIDS defining event, excluding mycobacterial and invasive fungal infections, is acceptable as long as it has resolved or the subject has been on stable treatment (e.g. opportunistic infection) for at least 12 weeks before screening (Visit 1). Note that prior oral thrush, candida esophagitis and cutaneous candida is acceptable.

Exclusion Criteria:

1. The following resistance mutations demonstrated at any time prior to starting trial therapy: V106A and/or Y188L

2. Female patients of child-bearing potential who:

have a positive serum pregnancy test at screening or during the study, are breast feeding, are planning to become pregnant, are not willing to use a barrier method of contraception.

3. Active Hepatitis B or C disease defined as HBsAg positive or HCV RNA positive with AST/ALT > DAIDS Grade 1

4. Acute/previous mycobacterial or invasive fungal infection requiring therapy or prophylaxis with drugs interfering with or significantly affected by the cytochrome P450 system

5. Use of investigational medications within 30 days before study entry or during the trial.

6. Use of concomitant drugs that may significantly reduce plasma levels of the study medications.

7. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g. interferon, cyclosporin, hydroxyurea, interleukin 2).

8. Patients currently treated with systemic ant-cancer chemotherapy

9. Inability to adhere to the requirements of the protocol, including active substance abuse, as defined by the investigator.

10. In the opinion of the investigator, likely survival of less than 12 months because of underlying disease.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• BILR 355 BS

• Placebo

Locations

Country	Name	City	State
Germany	Boehringer Ingelheim Investigational Site	Berlin
Germany	Boehringer Ingelheim Investigational Site	Bochum
Germany	Boehringer Ingelheim Investigational Site	Bonn
Germany	Boehringer Ingelheim Investigational Site	Erlangen
Germany	Boehringer Ingelheim Investigational Site	Frankfurt/Main
Germany	Boehringer Ingelheim Investigational Site	Hamburg
Germany	Boehringer Ingelheim Investigational Site	Hannover
Germany	Boehringer Ingelheim Investigational Site	Heidelberg
Germany	Boehringer Ingelheim Investigational Site	Mainz
Germany	Boehringer Ingelheim Investigational Site	Munchen
Germany	Boehringer Ingelheim Investigational Site	Ulm

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be reduction in plasma HIV-1 RNA from baseline to day 8, expressed in log10 copies/mm3.		day 8	No
Secondary	Virologic response at Day 8 and Day 35 using <400 copies/mL and 0.5, 1 and 1.5 log10 reduction in viral load from baseline		up to week 5	No
Secondary	Change from baseline in viral load at each visit		up to week 9	No
Secondary	Change from baseline in CD4+ cell counts at each visit		up to week 9	No
Secondary	Time averaged change from baseline in viral load through Days 8 and 35		up to week 5	No
Secondary	Number of reverse transcriptase (RT) mutations at baseline		up to week 5	No
Secondary	Number of NNRTI resistance-associated mutations at baseline (refer to Appendix 10.4)		up to week 5	No
Secondary	The presence of specific RT mutations (both in the list of NNRTI mutations and not in the list for exploratory purposes) at baseline		up to week 5	No
Secondary	The inhibitory quotient and minimum measured concentration of the analyte in plasma (Cmin)		up to Day 8	No
Secondary	Exploration of mutations that emerge with exposure to BILR 355 BS to determine the effect on both viral load and IC50 fold change from reference		up to week 5	No
Secondary	Area under the concentration-time curve of the analyte in plasma over the time interval 0 to 12 hours post-dose (AUC0-12h)		up to week 5	No
Secondary	Maximum measured concentration of the analyte in plasma (Cmax)		up to week 5	No
Secondary	Changes in total cholesterol, LDL, HDL and triglycerides from baseline to days 8 and 35		up to week 9	No
Secondary	Incidence of rash, hepatic events, and CNS adverse events		up to week 9	No
Secondary	Incidence of any adverse events (treatment related and unrelated)		up to week 9	No
Secondary	Incidence of laboratory test abnormalities		up to week 9	No
Secondary	Incidence of serious adverse events (including AIDS-defining events)		up to week 9	No
Secondary	Incidence of = DAIDS 2 Grade elevation in ALT/AST		up to week 9	No
Secondary	Incidence of AEs leading to discontinuation from the study		up to week 9	No